fexofenadine has been researched along with itraconazole in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cha, IJ; Choi, YG; Hong, WS; Lee, SS; Nguyen, PM; Shin, JG; Shon, JH; Yoon, YR | 1 |
| Shimizu, M; Sugawara, K; Tateishi, T; Uno, T | 3 |
| Miura, M; Suzuki, T; Tateishi, T; Uno, T | 1 |
| Miura, M; Uno, T | 1 |
| Srinivas, NR | 1 |
| Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N | 1 |
2 review(s) available for fexofenadine and itraconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical pharmacokinetics of fexofenadine enantiomers.
Topics: Antifungal Agents; Calcium Channel Blockers; Drug Interactions; Histamine H1 Antagonists; Humans; Itraconazole; Stereoisomerism; Terfenadine; Verapamil | 2010 |
6 trial(s) available for fexofenadine and itraconazole
| Article | Year |
|---|---|
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Topics: Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Double-Blind Method; Drug Interactions; Genes, MDR; Haplotypes; Histamine H1 Antagonists; Humans; Itraconazole; Male; Polymorphism, Genetic; Terfenadine | 2005 |
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Topics: Adult; Analysis of Variance; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Diltiazem; Drug Administration Schedule; Drug Interactions; Female; Histamine H1 Antagonists; Humans; Itraconazole; Male; Terfenadine; Time Factors | 2006 |
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Topics: Adult; Antifungal Agents; Cross-Over Studies; Drug Interactions; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Itraconazole; Japan; Male; Terfenadine | 2006 |
Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Itraconazole; Male; Middle Aged; Terfenadine | 2006 |
The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Drug Combinations; Drug Interactions; Female; Humans; Itraconazole; Male; Terfenadine | 2008 |
Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Itraconazole; Losartan; Polypharmacy; Terfenadine | 2016 |
3 other study(ies) available for fexofenadine and itraconazole
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Topics: Acetamides; Albuterol; Animals; Carbamates; Chromatography, Liquid; Diazepam; Diclofenac; Digitoxin; Humans; Itraconazole; Ketoprofen; Liver; Metabolic Clearance Rate; Mice; Mice, Transgenic; Naproxen; Pharmaceutical Preparations; Phenytoin; Piperidines; Pravastatin; Pyrimidines; Quinidine; Tandem Mass Spectrometry; Telmisartan; Terfenadine; Verapamil | 2020 |